Biopharmaceutical Performance of DiluCap: A Line of Functional Excipients Enhancing Dissolution Profiles of Minoxidil, Finasteride, Melatonin, and Naltrexone
May 2025
in “
PubMed
”
Studysummary In this study, researchers reported that hardshell capsules using the DiluCap® line of excipients demonstrated varying dissolution profiles under gastrointestinal-simulating conditions, with minoxidil and finasteride showing rapid release and melatonin and naltrexone displaying controlled release, indicating their suitability for different applications in compounding pharmacies. Our plain-language summary of this paper — not a Tressless recommendation.
The study evaluates the biopharmaceutical performance of DiluCap®, a line of functional excipients, in enhancing the dissolution profiles of minoxidil, finasteride, melatonin, and naltrexone in hard-shell capsules. The research highlights that minoxidil and finasteride capsules achieved rapid dissolution, while melatonin and naltrexone capsules demonstrated controlled release under gastrointestinal-simulating conditions. These findings emphasize the importance of selecting appropriate excipients to ensure the stability, compatibility, and efficacy of active pharmaceutical ingredients (APIs), thereby enhancing bioavailability and streamlining compounding processes in pharmacies.
